(Reuters) -Eli Lilly reported that its once-weekly insulin injection, efsitora, demonstrated consistent blood sugar reduction compared to daily insulins in two studies.
Lilly and Novo Nordisk are developing weekly injections for long-acting insulins, aiming to ease treatment burdens for diabetes patients.
Novo’s weekly injection, insulin icodec, has been recommended for approval in Europe and is under regulatory review in the United States. Advisers to the U.S. Food and Drug Administration are set to meet next week to discuss Novo’s application for approval.
Both drugmakers lead the market for GLP-1 agonists, which help control blood sugar levels and slow stomach emptying.
In one of the two studies, Lilly evaluated efsitora in patients using and not using GLP-1 therapies.
Lilly said efsitora was non-inferior to insulin degludec, sold as Tresiba by Novo, in reducing blood sugar levels in both sets of patients.
At the end of 52 weeks, patients using efsitora experienced a 1.34% reduction in their A1C levels, compared to a 1.26% reduction for those using insulin degludec. The trial involved patients using insulin for the first time.
Lilly plans to present detailed data from this study at a medical conference later this year.
In these studies, participants using weekly insulin exhibited outcomes comparable to those of daily doses. This breakthrough could revolutionize diabetes treatment, offering patients more convenient and effective options.
The implications of Lilly Insulin Studies extend beyond medical advancements. Healthcare providers may need to adapt their protocols to incorporate these new findings, ensuring optimal patient care and outcomes.
read more
image source
